CD137/CD137L在食管癌中表达与预后的相关性分析

The expression of CD137/CD137L in esophageal cancer and its correlation with prognosis

目的研究食管癌中CD137/CD137L的表达情况,并分析两者在食管癌中表达的意义及其与预后的关系。方法以购自上海芯超生物科技有限公司的食管癌组织芯片为研究对象,采用免疫组织化学方法检测组织芯片中87例食管癌组织及其相应的癌旁组织中CD137/CD137L的表达情况;采用χ~2检验或Fisher's精确检验的方法分析食管癌及癌旁组织中CD137/CD137L的表达与临床病理特征的关系;采用Kaplan-Meier法分析CD137/CD137L的表达与食管癌患者预后的关系。结果在87例食管癌组织和相应的癌旁组织中CD137的阳性表达率分别为36.8%和72.4%,两者比较差异有统计学意义(P<0.05)。在87例食管癌组织和相应的癌旁组织中CD137L的阳性表达率分别为57.5%和96.6%,两者比较差异有统计学意义(P<0.05)。食管癌中CD137表达阳性率与浸润深度相关(P<0.05),而与年龄、性别、肿瘤部位、分化程度、临床分期均不相关(P>0.05)。食管癌中CD137L表达与临床分期相关(P<0.05),而与年龄、性别、肿瘤部位、分化程度、浸润深度均不相关(P>0.05)。CD137表达与食管癌患者的预后不相关(P=0.6301),CD137L表达与食管癌患者的预后相关(P=0.0368)。结论 CD137L的表达水平是影响食管癌患者预后的独立因素;CD137/CD137L可能在食管癌的抗肿瘤免疫中发挥重要作用。

Objective To investigate the expression of CD137/CD137L in esophageal cancer, and analyze the signifi- cance and correlation with disease prognosis. Methods The esophageal tissue chip purchased from Xinchao Biological Technology co. LTD, Shanghai was taken as the research object. Immunohistochemical method was used to detect the expression of CD137/CD137L of 87 cases of esophageal cancer tissues and its corresponding adjacent tissues in the tis- sue chip. Chi-square test or Fisher＇s inspection method was used to analyze the relationship of the expression of CD137/CD137L and the clinical pathological features in esoptageal cancer tissue and corresponding adjacent tissue. I Kaplan-Meier method was used to analyze the relationship between the expression of CD137/CD137L and the prognosis of esophageal cancer. Results The positive expression rate of CD137 in 87 cases esophageal cancer tissues and corre- sponding adjacent tissue was 36.8% and 72.4% respectively, the difference was statistically significant （P 〈 0.05）. Thepositive expression rate of CD137L in 87 cases esophageal cancer tissues and corresponding adjacent tissue was 57.5% and 96.6% respectively, the difference was statis- tically significant （P 〈 0.05）. The positive expression rate of CD137 in esophageal carcinoma tissues was related to depth of invasion （P 〈 0.05）, but no relation with gender, age, tumor site, differentiated degree and clinical stage（P 〉 0.05）. The positive expression rate of CD137L in esophageal care!noma tissues was related to clinical stage （P 〈 0.05）, but no relation with gender, age, tumor site, differentiated degree and depth of invasion （P 〉 0.05）. The expression rate of CD137 was not related with the prognosis of esophageaLcaneer （P=0.6301）. The expression rate of CD137L was related with the prognosis of esophageal cancer （P=-0.0368）. Conclusion The expression level of CD137L is a prognostic factor of esophageal cancer; CD137/CD137L may play an important role in antitumor immunity of esophageal cancer.